CORONAVIRUS/Taiwan COVID vaccine maker to apply for EUA after promising Phase II trial results
06/10/2021 05:39 PM
Taipei, June 10 (CNA) Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after unblinding the results of its Phase II clinical trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
More in CORONAVIRUS
![Taiwan reports 5,544 new COVID-19 cases, 28 deaths]()
Taiwan reports 5,544 new COVID-19 cases, 28 deathsTaiwan's Central Epidemic Command Center (CECC) on Monday reported 5,544 new cases of COVID-19 and 28 deaths from the disease.03/20/2023 05:12 PM![Taiwan reports 8,419 new COVID-19 cases, 43 deaths]()
Taiwan reports 8,419 new COVID-19 cases, 43 deathsTaiwan's Central Epidemic Command Center (CECC) on Sunday reported 8,419 new cases of COVID-19 and 43 deaths from the disease.03/19/2023 03:38 PM![Taiwan reports 8,026 new COVID-19 cases, 35 deaths]()
Taiwan reports 8,026 new COVID-19 cases, 35 deathsTaiwan's Central Epidemic Command Center (CECC) reported 7,825 new domestic COVID-19 cases on Saturday, adding that there were 201 imported cases and 35 deaths.03/18/2023 04:47 PM
Latest
- Sports
Taiwan's top shuttlers drop down world badminton rankings
03/21/2023 09:39 PM - Politics
U.S. likely to support Taiwan in event of Chinese invasion: O'Brien
03/21/2023 08:40 PM - Politics
No notification from Honduras ending diplomatic ties yet: MOFA
03/21/2023 07:11 PM - Business
Taiwan shares rebound on U.S. gains
03/21/2023 06:27 PM - Society
Mpox jabs booked up in under 10 minutes as Taiwan sees 4 new cases
03/21/2023 06:11 PM